For the most up-to-date Primary/Preferred Drug List visit www.caremark.com
The Caremark Primary/Preferred Drug List is a guide within select therapeutic categories for clients and their plan participants. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand name medicine to treat a condition. These preferred brand name medicines are listed to help identify products that are clinically appropriate and cost-effective. PLAN PARTICIPANT HEALTHCARE PROVIDER
Your benefit plan provides you with a prescription benefit program
Your patient is covered under a prescription benefit plan administered by
administered by Caremark. Ask your doctor to consider prescribing, when
Caremark. As a way to help manage healthcare costs, authorize generic
medically appropriate, a preferred medicine from this list. Take this list
substitution whenever possible. If you believe a brand name product is
along when you or a covered family member sees a doctor.
necessary, consider prescribing a brand name on this list. Please note: Please note:
■ Your specific prescription benefit plan design may not cover certain
■ Generics should be considered the first line of prescribing.
categories, regardless of their appearance in this document.
■ This drug list is not inclusive nor does it guarantee coverage, but
■ For specific information regarding your prescription benefit coverage and
represents a summary of prescription coverage.
co-pay1 information, please visit our Web site at www.caremark.com,
■ The plan participant’s specific prescription benefit plan may have
or contact a Caremark Customer Care representative.
a different co-pay1 for specific products on the list.
■ Caremark may contact your doctor after receiving your prescription to
■ Unless specifically indicated, drug list products will include all
request consideration of a drug list product or generic equivalent. This
may result in your doctor prescribing, when medically appropriate, a
■ Log in to www.caremark.com to check coverage and co-payments1
different brand name product or generic equivalent in place of your
§ NUCLEOSIDE PROTEASE INHIBITORS AROMATASE INHIBITORS REVERSE-TRANSCRIPTASE ANTIBACTERIALS INHIBITORS ALKYLATING AGENTS § CEPHALOSPORINS LUTEINIZING § ERYTHROMYCINS/ HORMONE-RELEASING MACROLIDES HORMONE (LHRH) AGONISTS ANTIMETABOLITES § FLUOROQUINOLONES NUCLEOSIDE REVERSE-TRANSCRIPTASE ANTIVIRALS INHIBITOR COMBINATIONS MISCELLANEOUS AGENTS § CYTOMEGALOVIRUS § ACE INHIBITORS § ANTIFUNGALS § HEPATITIS AGENTS ACE INHIBITOR/CALCIUM CHANNEL BLOCKERS ANTIRETROVIRALS NUCLEOTIDE REVERSE-TRANSCRIPTASE FUSION INHIBITORS TYROSINE KINASE INHIBITORS INHIBITORS NON-NUCLEOSIDE § ADRENOLYTICS, CENTRAL § HERPES AGENTS REVERSE-TRANSCRIPTASE INHIBITORS § INFLUENZA AGENTS HORMONAL ANGIOTENSIN II ANTINEOPLASTIC AGENTS RECEPTOR ANTAGONISTS/ COMBINATIONS ANTIANDROGENS CASODEX ANTIESTROGENS Your specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. ORAL ESTROGEN/ § ANTIARRHYTHMICS ANTIDEMENTIA § PROTON PUMP PROGESTINS INHIBITORS ANDROGENS ANTILIPEMICS ANTILIPEMIC COMBINATIONS PROTON PUMP INHIBITORS ANTIDIABETICS WITH ANTI-INFECTIVE FERTILITY REGULATORS § BILE ACID RESINS ANTIDEPRESSANTS ALPHA-GLUCOSIDASE § MISCELLANEOUS AGENTS INHIBITORS § RECTAL STEROIDS CHOLESTEROL ABSORPTION INHIBITORS MONOAMINE OXIDASE INSULINS INHIBITORS (MAOIs) SALIVA STIMULANTS § FIBRATES HUMAN GROWTH HORMONES § HMG-CoA REDUCTASE § SELECTIVE SEROTONIN INHIBITORS REUPTAKE INHIBITORS § BENIGN PROSTATIC INSULIN SENSITIZERS HYPERPLASIA INSULIN SENSITIZER/ SEROTONIN ERECTILE DYSFUNCTION BIGUANIDE COMBINATIONS § BETA-BLOCKERS NOREPINEPHRINE § PROGESTINS PHOSPHODIESTERASE REUPTAKE INHIBITORS INHIBITORS (SNRIs) 3 INSULIN SENSITIZER/ SELECTIVE ESTROGEN § CALCIUM CHANNEL SULFONYLUREA RECEPTOR MODULATORS BLOCKERS COMBINATIONS ALPROSTADIL AGENTS § ANTIPARKINSONIANS MEGLITINIDES § THYROID SUPPLEMENTS CALCIUM CHANNEL § URINARY BLOCKER/ANTILIPEMIC SUPPLIES ANTISPASMODICS COMBINATIONS § ANTIEMETICS § DIGITALIS GLYCOSIDES ANTIPSYCHOTICS ENDOTHELIN RECEPTOR ANTAGONISTS BISPHOSPHONATES ANTIOBESITY– § ANTICOAGULANTS FAT ABSORPTION DECREASING AGENTS NITRATES § ATTENTION DEFICIT § PLATELET AGGREGATION SUBLINGUAL HYPERACTIVITY CONTRACEPTIVES INHIBITORS § ANTISPASMODICS DISORDER/NARCOLEPSY § MONOPHASIC § TRANSDERMAL § TRIPHASIC § CHOLELITHOLYTICS IMMUNOMODULATORS EXTENDED CYCLE INFLAMMATORY BOWEL INTERFERONS § ANTICONVULSANTS TRANSDERMAL § ORAL AGENTS MIGRAINE SELECTIVE SEROTONIN INTERFERON/ANTIVIRAL AGONISTS COMBINATIONS ESTROGENS § RECTAL AGENTS IMMUNOSUPPRESSANTS MULTIPLE SCLEROSIS ANTIMETABOLITES § LAXATIVES § TRANSDERMAL, ESTROGENS PANCREATIC ENZYMES § CALCINEURIN INHIBITORS § MUSCULOSKELETAL THERAPY AGENTS Your specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. RAPAMYCIN DERIVATIVES § STEROIDS BETA-BLOCKERS, SELECTIVE § BETA AGONISTS DERMATOLOGY CARBONIC ANHYDRASE INHIBITORS FOLIC ACID COMBINATIONS § MISCELLANEOUS SKIN § DECONGESTANT/ AND MUCOUS MEMBRANE CARBONIC ANHYDRASE § PRENATAL VITAMINS EXPECTORANTS INHIBITOR/BETA-BLOCKERS § ACTINIC KERATOSIS LEUKOTRIENE RECEPTOR OPHTHALMIC IMMUNOMODULATORS § ANTIBIOTICS ANAPHYLAXIS TREATMENT ANTAGONISTS § ANTIALLERGICS PROSTAGLANDINS NASAL ANTIHISTAMINES § ANTIFUNGALS § ANTI-INFECTIVE/ § SYMPATHOMIMETICS § ANTICHOLINERGICS § NASAL STEROIDS ANTI-INFLAMMATORIES ANTIPSORIATICS ANTICHOLINERGIC/ § ANTI-INFLAMMATORIES, ANTI-INFECTIVES BETA AGONISTS IMMUNOMODULATORS STEROIDAL STEROID/BETA AGONISTS § ANTI-INFECTIVE/ § ANTI-INFLAMMATORIES, ANTI-INFLAMMATORIES NONSTEROIDAL ANTIHISTAMINES, § LOCAL ANALGESICS STEROID INHALANTS LOW SEDATING § ROSACEA § BETA-BLOCKERS, § ANTIHISTAMINE/ NONSELECTIVE DECONGESTANTS § XANTHINES QUICK REFERENCE BRAND PRIMARY/PREFERRED DRUG LIST Your specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. FOR YOUR INFORMATION: Generics should be considered the first line of prescribing. This Caremark Drug List is not inclusive nor does it guarantee coverage, but represents a summary of prescription coverage. Specific prescription benefit plan design may not cover certain categories, regardless of their appearance in this document. The plan participant's prescription benefit plan may have a different co-pay1 for specific products on the list. Unless otherwise indicated, drug list products will include all dosage forms. Listed products may be available generically in certain strengths or dosage forms. Log in to www.caremark.com to check coverage and co-payments for a specific medicine.
§ Generics are available in this class and should be considered as the first line of prescribing.
1 Co-payment or co-pay means the amount a plan participant is required to pay for a prescription in accordance with a Plan, which may be a deductible, a percentage of the
prescription price, a fixed amount or other charge, with the balance, if any, paid by a Plan.
2 Atacand should be reserved for patients who meet CHARM (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity) trial criteria. 3 Indicates the proposed mechanism of action, based on the American Psychiatric Association Summary of Treatment Recommendations. 4 Higher co-payments may apply depending on the plan participant's specific prescription benefit plan. Log in to www.caremark.com to find the co-payment under a specific plan. 5 An Accu-Chek or OneTouch blood glucose meter will be provided at no charge by the manufacturer to those individuals currently using a meter other than Accu-Chek or OneTouch.
For more information on how to obtain a blood glucose meter, call toll-free: 1-800-588-4456. Your privacy is important to us. Our employees are trained regarding the appropriate way to handle your private health information. Caremark may receive rebates, discounts and service fees from pharmaceutical manufacturers for certain listed products. This Caremark Drug List contains prescription brand name medicines that are registered or trademarks of pharmaceutical manufacturers that are not affiliated with Caremark Inc. Listed products are for informational purposes only and are not intended to replace the clinical judgment of the prescriber.
2006 Caremark Inc. All rights reserved. www.caremark.com
28 year old male Major depression, recurrent, moderate and ADHD Two year history of constant depressive symptoms including: o depressed mood o fatigue o difficulty concentrating o poor appetite o weight loss o anxiety o insomnia o anhedonia o low self-esteem o thoughts of suicide Medications of Trazodone and Strattera Course of 20 treatments over 4 weeks 6 taper tre
PRE-COMMITMENT AS A STRATEGY FOR MINIMIZING GAMBLING-RELATED HARM Professor, Faculty of Health Sciences & Coordinator, Alberta Gaming Research Institute Abstract Pre-commitment is a relatively new harm minimization strategy for problem gambling. To date, its primary use has been in casino self-exclusion programs, a few Internet gambling sites, and to limit land-based EGM play in a few juris